Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840830 | 0.98 | ALDH1A1 (0.55) | TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2322917 | 0.84 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTKCNJ1 | |
| SCHEMBL29805413 | 0.84 | PLD1 (0.49) | ALDH1A1KDM4EKCNJ1 | |
| SCHEMBL1124372 | 0.84 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA | |
| SCHEMBL1569943 | 0.84 | PLD1 (0.49) | ALDH1A1KDM4EKCNJ1 | |
| SCHEMBL30287647 | 0.84 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA | |
| SCHEMBL25082374 | 0.82 | KCNJ1 (0.44) | TRIM24TRIM33ALDH1A1MAPTKCNJ1 | |
| SCHEMBL844318 | 0.82 | KDM4E (0.56) | ALDH1A1SMN1; SMN2KDM4EMAPTKCNJ1 | |
| SCHEMBL14235512 | 0.82 | KCNJ1 (0.44) | ALDH1A1SMN1; SMN2KDM4EMAPTKCNJ1 | |
| SCHEMBL21411324 | 0.81 | MAPT (0.47) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| CN-113563327-B | Novel mesoionic compound and synthesis and application thereof | 东莞市东阳光农药研发有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3774736-B1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3774736-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | Neuropore Therapies, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009095394-A1 | DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-08-06 | — | — | WO | disclosed |
| US-6462047-B1 | CONTAINING 5- OR 6-MEMBERED OXYGEN, NITROGEN AND/OR SULFUR HETEROARYL GROUP; ANGINA, HYPERTENSION, RESPIRATORY DISTRESS, CONGESTIVE HEART FAILURE, RENAL FAILURE, ATHEROSCLEROSIS, INFLAMMATORY DISEASES, STROKES, BRONCHITIS, ASTHMA | ICOS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| EP-1114048-A1 | CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS | Bombrun, Agnès (FR) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015639-A1 | CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | TRIM24 1887/4885TRIM33 3127/4885ALDH1A1 4464/4885 |
| US-20100272656-A1 | Flavor Molecules | TAS2R30, TAS2R31, TAS2R1 | TRIM24 2967/4885TRIM33 2174/4885ALDH1A1 683/4885 |
| US-20100040753-A1 | FLAVOR MOLECULES | TAS2R30, TAS2R31, TAS2R1 | TRIM24 2967/4885TRIM33 2174/4885ALDH1A1 683/4885 |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | TRIM24 1887/4885TRIM33 3127/4885ALDH1A1 4464/4885 |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | TRIM24 1887/4885TRIM33 3127/4885ALDH1A1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.